Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults
Crossref DOI link: https://doi.org/10.1007/s40121-023-00794-1
Published Online: 2023-04-25
Published Print: 2023-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Schmidt, Pete
Gong, Jean
Narayan, Kristin
Gupta, Deepali
Engler, Frank
Li, Yong
Copans, Amanda
Campanaro, Ed
Text and Data Mining valid from 2023-04-25
Version of Record valid from 2023-04-25
Article History
Received: 26 January 2023
Accepted: 22 March 2023
First Online: 25 April 2023